A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma

Glembatumumab vedotin (CDX-011, GV) is a fully human Immunoglobulin G2 monoclonal antibody directed against glycoprotein NMB coupled via a peptide linker to monomethyl auristatin E (MMAE), a potent cytotoxic microtubule inhibitor. This phase II study evaluated the overall response rate and safety of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Hasanov, Merve, Rioth, Matthew J., Kendra, Kari, Hernandez-Aya, Leonel, Joseph, Richard W., Williamson, Stephen, Chandra, Sunandana, Shirai, Keisuke, Turner, Christopher D., Lewis, Karl, Crowley, Elizabeth, Moscow, Jeffrey, Carter, Brett, Patel, Sapna
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7465139/
https://ncbi.nlm.nih.gov/pubmed/32823698
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12082270
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars